|
|
Post by harryx1 on Mar 5, 2019 11:34:13 GMT -5
|
|
|
|
Post by harryx1 on Mar 5, 2019 11:41:56 GMT -5
|
|
|
|
Post by mannmade on Mar 5, 2019 11:44:00 GMT -5
So this could mean Trep T rev$ as early as 2020?
|
|
|
|
Post by Clement on Mar 5, 2019 11:44:47 GMT -5
from today's Zacks article (Harry's post):
"While the pilot DTC campaign in 2017 was aired in a dozen markets, the current ad commenced in the second half of January across national cable networks and local TV stations. Additional marketing initiatives began in February. MannKind intends to remain flexible on overall spend on the campaign as the marketing push continues.
These ads seem to be a step in the right direction for the company. On the earnings call (2/26/19) management stated that it already resulted in a significant spike in copay card downloads (in one month got as many downloads as a normal year), while hits to the Afrezza website was up five-fold. "
|
|
|
|
Post by harryx1 on Mar 5, 2019 11:48:18 GMT -5
Additionally, we expect to hear from MannKind’s partner, Receptor Life Sciences, on the development of Dronabinol, an inhaled therapeutic for cancer pain.
|
|
|
|
Post by seanismorris on Mar 5, 2019 12:14:33 GMT -5
A positive article that goes in the face of disappointing scrips.
This is good: Our sum-of-the-parts calculation puts total value of the company at ~$4.25/share.
They’re basing much of the projection on non Afrezza items. My projection of $5 by the end of March is struggling due to scripts...
|
|
